Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer
Roche announced today top-line results of the Phase III MARIANNE study. The study evaluated three HER2-targeted regimens - Kadcyla (trastuzumab emtansine) plus Perjeta (pertuzumab), Kadcyla alone, and Herceptin (trastuzumab) plus taxane chemotherapy - in people with previously untreated (first line) advanced HER2-positive breast cancer.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Pharmaceuticals | Study